As part of our ongoing aim to bring you reports of new developments, we have added a review of a recent study update on the AVENANCE trial: Real-World Effectiveness of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma.
Independent commentary for the review has been provided by Associate Professor Andrew Weickhardt, a medical oncologist at the Olivia Newton-John Cancer and Wellness Centre in Melbourne.
Please login below to download this issue (PDF)